- Open Access
Erratum to: Fish oil: what the prescriber needs to know
Arthritis Research & Therapy volume 8, Article number: 402 (2006)
The original article was published in Arthritis Research & Therapy 2005 8:202
It has been brought to our attention that there were a number of typographical errors in one section of our recent article  published in December 2005.
All corrections apply to the section entitled, 'Biochemical rationale; Eicosanoids: cyclo-oxygenase pathway'.
The second paragraph should read:
The usual substrate for the COX isozymes is the n6 LC PUFA arachidonic acid (AA; C20:4n-6). Eicosapentaenoic acid (EPA; C20:5n-3), which is present in fish oil, differs from AA only by the presence of its n3 bond (Fig. 1).
The last sentence of the third paragraph should read:
Thus, the net effect of fish oil is to reduce the production of proinflammatory and pro-thrombotic eicosanoids (PGE2 and TXA2, respectively) but not the vascular patency factor prostacyclin (PGI2; Fig. 2).
Finally, the first 20-Carbon fatty acid homologue pictured in Figure 1 (C20:3 n-9) is eicosatrienoic acid, rather than oleic acid.
Cleland LG, James MJ, Proudman SM: Fish oil: what the prescriber needs to know. Arthritis Research & Therapy. 2006, 8: 202-10.1186/ar1876.
The online version of the original article can be found at 10.1186/ar1876
About this article
Cite this article
Cleland, L.G., James, M.J. & Proudman, S.M. Erratum to: Fish oil: what the prescriber needs to know. Arthritis Res Ther 8, 402 (2006) doi:10.1186/ar1981